Talk:BlephEx

"Dry products", "dry eye products", or "products for dry eyes"?

minor nitpicky, but "dry products" sounds like a typo to me. is this paragraph talking about "products for treating dry eye", or literally "dry products to treat dry eyes"? SalvaStalker (talk) 13:24, 17 January 2024 (UTC)

Lead overstates treatment use; FDA warning letter and 2024 RCT omitted

I have used public FDA and journal records for this information about BlephEx, LLC. The sources below are published.

Feedback and thoughts from other editors are welcome. WikiMedicalFactChecker (talk) 22:52, 2 October 2026 (UTC)

1. The lead is a treatment claim, not the FDA classification

The first sentence currently says BlephEx is a medical device "used ... to treat blepharitis and dry eye disease." That is not an FDA-approved or 510(k)-cleared indication.

FDA product code PYU ("sponge, eyelid cleaning, powered") is a class I, 510(k)-exempt type for a healthcare professional to cleanse the eyelid margins and eyelashes, subject to 21 CFR 878.9. Class I exemption is not approval. Cosmetics are a different FDA category; FDA did not approve this product as a cosmetic.

• https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?id=PYU
• https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-878/subpart-E/section-878.4820

Proposed lead is in the article edit I am also making, sourced to those pages and to the warning letter below.

2. FDA warning letter MARCS-CMS 725861 (3 June 2026)

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/blephex-llc-725861-06032026

Secondary coverage: Joanne S. Eglovitch, Regulatory Focus (RAPS), 10 July 2026. https://www.raps.org/resource/fda-admonishes-companies-for-marketing-unauthorized-products-making-misleading-claims.html

The letter, addressed to James M. Rynerson as owner and president of BlephEx, LLC, states that in 2017 the firm described the product to FDA as for eyelid cleaning/hygiene and "not for the cure, treatment or mitigation of any disease or condition," and said it was not intended to be used as a treatment; FDA then treated that description as class I PYU, 510(k)-exempt, subject to 21 CFR 878.9; the firm later marketed the BlephEx Powered Eyelid Cleaning Sponge for treating blepharitis and dry eye disease and for pre-cataract and pre-LASIK patients; as described and marketed, FDA found the product adulterated (no PMA or IDE) and misbranded (different intended use without a 510(k)); required GUDID information had not been submitted. The letter also cites manufacturing and complaint-handling deficiencies.

A warning letter is not a court finding. It is a published FDA statement and should be summarised as such, not omitted while the article repeats the treatment claims FDA objected to.

3. 2024 Freiburg randomised sham-controlled trial

Helena Siegel, Annika Merz, Nikolai Gross, Marie-Christine Bründer, Daniel Böhringer, Thomas Reinhard, Philip Maier. "BlephEx-treatment for blepharitis: a prospective randomized placebo-controlled trial." BMC Ophthalmology 24, 503 (2024). doi:10.1186/s12886-024-03765-3. PMID 39558272. PMC 11575124.

Design as stated by the authors: prospective, randomised, double-masked, sham-controlled; 42 patients; 20 analysed in each arm after two dropouts. Authors' conclusion, verbatim: "No significant difference in outcomes was observed between patients who underwent BlephEx therapy and those who received sham treatment. BlephEx treatment cannot be recommended for treating blepharitis." Competing interests: none declared.

The article currently cites the inventor's own 2016 paper as if it were independent evidence of a 60 to 66 percent increase in tear breakup time.

4. Unsourced promotional biomedical claims (WP:MEDRS)

Please delete or rewrite: unsourced "board-certified ophthalmologist"; "Two independent studies demonstrate a 60%-66% increase in tear break up time"; patients making their own tears / stopping artificial tears; the "Cost to patient and society" section, which uses a 2011 dry-eye cost paper that does not study BlephEx.

5. Inventor's book, primary source for his claims only

James M. Rynerson, Dry Eyes: The Cause, The Cure (2022). Cover: "THE CAUSE, THE CURE". Page ix: "These are my opinions which are not based on any randomized, double blind studies." Usable only for what the inventor wrote, not for efficacy.

6. What I am not asking to add

Unpublished claims or social-media advertisements (WP:OR, WP:SYNTH, WP:BLP).

WikiMedicalFactChecker (talk) 02:40, 2 October 2026 (UTC)